Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica J Lin

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
The New England Journal of Medicine|January 10, 2024
Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsHarshabad Singh, Yvonne Y Li, Liam F Spurr, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation StatusBiagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Cell|October 16, 2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerPatrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, et al.
Nature|July 5, 2023
Therapy-induced APOBEC3A drives evolution of persistent cancer cellsHideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2024
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLCAmin H Nassar, Ritujith Jayakrishnan, Jamie Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global ConsortiumSarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
The New England Journal of Medicine|January 10, 2024
Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsHarshabad Singh, Yvonne Y Li, Liam F Spurr, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation StatusBiagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Cell|October 16, 2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerPatrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, et al.
Nature|July 5, 2023
Therapy-induced APOBEC3A drives evolution of persistent cancer cellsHideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2024
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLCAmin H Nassar, Ritujith Jayakrishnan, Jamie Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global ConsortiumSarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Pageof 10